Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2026-02-20 @ 10:58 PM
Study NCT ID:
NCT01506167
Status:
COMPLETED
Last Update Posted:
2018-05-14
First Post:
2012-01-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}], 'ancestors': [{'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000068258', 'term': 'Bevacizumab'}, {'id': 'C519688', 'term': 'XELOX'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D000069287', 'term': 'Capecitabine'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 719}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-07-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-05', 'completionDateStruct': {'date': '2017-03-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-05-08', 'studyFirstSubmitDate': '2012-01-05', 'studyFirstSubmitQcDate': '2012-01-05', 'lastUpdatePostDateStruct': {'date': '2018-05-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2012-01-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-03-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants with Serious Adverse Events (SAEs)', 'timeFrame': '1.5 years', 'description': "An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires new in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes."}, {'measure': 'Percentage of Participants with Grade 3-5 Avastin Related Adverse Events', 'timeFrame': '1.5 years', 'description': 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. Adverse events were graded according to NCI-CTCAE, v4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0).'}, {'measure': 'Progression-Free Survival', 'timeFrame': '1.5 years', 'description': 'Progression-Free Survival (PFS) was defined as the number of days from start of first-line therapy administration (earliest date of either the start of chemotherapy regimen administration or the start of Avastin) to the date of first occurrence of investigator-assessed disease progression or death. PFS was assessed using Kaplan-Meier method.'}, {'measure': 'Overall Survival', 'timeFrame': '1.5 years', 'description': 'Overall Survival (OS) is defined as the number of days from the start of first-line therapy (earliest date of either the start of chemotherapy regimen administration or the start of Avastin) to death by any cause.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants with Avastin Related Adverse Events of Special Interest', 'timeFrame': '1.5 years', 'description': 'Adverse events of special interest (AESIs) are defined by their possible association with Avastin® treatment. The adverse events of special interest in this study include all grades of gastrointestinal perforation, fistulae, arterial and venous thromboembolic events, congestive heart failure and pulmonary haemorrhages; and Grade 2-5: hypertension, wound healing complications, proteinuria and mucocutaneous haemorrhages.'}, {'measure': 'Reasons for Discontinuation of Avastin', 'timeFrame': '1.5 years'}, {'measure': 'Median Progression Free Survival from Four Avastin Studies', 'timeFrame': '1.5 years (ACORN)', 'description': 'PFS was defined as the number of days from start of first-line therapy administration (earliest date of either the start of chemotherapy regimen administration or the start of Avastin) to the date of first occurrence of investigator-assessed disease progression or death. The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only. Median PFS is presented for data from other registration trials and similar observational studies.'}, {'measure': 'Median Overall Survival from Four Avastin Studies', 'timeFrame': '1.5 years (ACORN)', 'description': 'OS is defined as the number of days from the start of first-line therapy (earliest date of either the start of chemotherapy regimen administration or the start of Avastin) to death by any cause. The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only. Median OS is presented for data from other registration trials and similar observational studies.'}, {'measure': 'Percentage of Participants with Comparative AEs from Four Avastin® Studies', 'timeFrame': '1.5 years (ACORN)', 'description': 'Comparative AEs included Gastrointestinal perforation; Haemorrhage (specific grade); All Haemorrhages; Hypertension; and Arterial thromboembolic events (cerebrovascular accident, myocardial infarction, transient ischaemic attack and other). The specific grade of haemorrhage was 3/4 for BRITE, 3/4 for BEAT and 3-5 for ARIES. The specific grade for ACORN was unknown. The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Median Age of Participants in Four Avastin® Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Percentage of Participants Over (or equal to) 75 Years of Age in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Percentage of Males and Females in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Eastern Cooperative Oncology Group (ECOG) Performance Status in Four Avastin Studies', 'timeFrame': '1.5 years (ACORN)', 'description': "ECOG Performance Status measured on-therapy (time between first dose and last dose date) assessed participant's performance status on 5 point scale: 0 is equal to (=) fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than \\[\\>\\] 50% of waking hours \\[hrs\\]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \\>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only."}, {'measure': 'Race/Ethnicity of Participants in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Percentage of Participants at Stage IV (at diagnosis) in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Percentage of Participants that Received Previous Systematic Treatment for CRC in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Sites of CRC in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Percentage of Participants with Primary Resection in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Metastatic Sites of CRC in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Ongoing Patient Medical Conditions in Four Avastin Studies', 'timeFrame': 'Baseline', 'description': 'The BRITE, BEAT and ARIES trials were conducted outside of the UK unlike the ACORN trial which was conducted in England only.'}, {'measure': 'Weeks of Further Treatment After 1st Line Chemotherapy', 'timeFrame': 'From disease progression until end of study.', 'description': 'Number of weeks of further chemotherapy regimen administered after 1st line treatment.'}, {'measure': 'Quality of Life as Assessed by the Euro-Quality of Life-5 Dimensions (EQ-5D) Weighted Index Score', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy', 'description': 'The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either "no problems", "slight problems", "moderate problems", "severe problems" or "extreme \\[problem\\]/unable to perform" in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D weighted index score ranging from -0.59 (extreme problems) to +1 (no problems) where a negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.'}, {'measure': 'Quality of Life as Assessed by the Euro-Quality of Life-5 Dimensions (EQ-5D) Crosswalk Index Score', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy', 'description': 'The EQ-5D is composed of 5 single-item measures where participants responded to questions assessing health status by responding with either "no problems", "slight problems", "moderate problems", "severe problems" or "extreme \\[problem\\]/unable to perform" in the following categories: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Based on population surveys, an algorithm was used to combine the responses to each of these 5 measures into 1 single EQ-5D index score ranging from -0.59 (extreme problems) to +1 (no problems) where a negative value indicated a worsening of perceived quality of life and a positive value indicated an improvement of perceived quality of life.'}, {'measure': 'Response to the Burden of Illness Question: In the last three months how many times have health care professionals been to your home?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: In the last three months how many times have you seen health care professionals at your GP Surgery or day centre?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: In the last three months how many nights in total did you spend in hospital/hospice?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: In the last three months how many times did you visit the imaging department for these examinations?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: What was your employment status before diagnosis?', 'timeFrame': 'Baseline'}, {'measure': 'Response to the Burden of Illness Question: What is your employment status now?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: Has your cancer resulted in you seeking support services?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: Has a previously employed family member had to take time off work to care for you?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}, {'measure': 'Response to the Burden of Illness Question: Has your cancer resulted in a family member seeking support?', 'timeFrame': 'Baseline and 3, 6, 9, 12, 15, 18, 21, 24 and 27 Months post chemotherapy'}]}, 'oversightModule': {'isFdaRegulatedDrug': False}, 'conditionsModule': {'conditions': ['Colorectal Cancer']}, 'referencesModule': {'references': [{'pmid': '31451367', 'type': 'DERIVED', 'citation': 'Khakoo S, Chau I, Pedley I, Ellis R, Steward W, Harrison M, Baijal S, Tahir S, Ross P, Raouf S, Ograbek A, Cunningham D; ACORN investigators. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clin Colorectal Cancer. 2019 Dec;18(4):280-291.e5. doi: 10.1016/j.clcc.2019.07.003. Epub 2019 Jul 11.'}]}, 'descriptionModule': {'briefSummary': 'This prospective, multi-center, observational study will assess the safety and efficacy of Avastin (bevacizumab) in daily practice in patients with metastatic colorectal cancer who have received no previous treatment for advanced disease and are receiving Avastin in combination with a standard of care first-line chemotherapy regimen. Data will be collected for 1.5 years or until death.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'Adult patients diagnosed with metastatic colorectal cancer', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Metastatic colorectal cancer with no previous systemic treatment for advanced disease\n* Receiving Avastin in combination with a first-line standard of care chemotherapy regimen\n* Avastin initiated at the same time as first-line chemotherapy regimen\n\nExclusion Criteria:\n\n* Investigational, non-standard of care first-line chemotherapy regimen for treatment of metastatic colorectal cancer\n* Contraindication to Avastin'}, 'identificationModule': {'nctId': 'NCT01506167', 'briefTitle': 'An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': 'An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma', 'orgStudyIdInfo': {'id': 'ML27971'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Bevacizumab and Capecitabine/Oxaliplatin', 'description': 'Participants who receive bevacizumab in combination with capecitabine/oxaliplatin', 'interventionNames': ['Drug: Bevacizumab', 'Drug: Capecitabine/Oxaliplatin']}, {'label': 'Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin', 'description': 'Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin', 'interventionNames': ['Drug: Bevacizumab', 'Drug: Fluorouracil/Folinic Acid/Oxaliplatin']}, {'label': 'Bevacizumab and Capecitabine', 'description': 'Participants who receive bevacizumab in combination with capecitabine', 'interventionNames': ['Drug: Bevacizumab', 'Drug: Capecitabine']}, {'label': 'Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan', 'description': 'Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan', 'interventionNames': ['Drug: Bevacizumab', 'Drug: Fluorouracil/Folinic Acid/Irinotecan']}, {'label': 'Bevacizumab and Capecitabine/Irinotecan', 'description': 'Participants who receive bevacizumab in combination with capecitabine/irinotecan', 'interventionNames': ['Drug: Bevacizumab']}, {'label': 'Bevacizumab and Fluorouracil +/- Folinic Acid', 'description': 'Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid', 'interventionNames': ['Drug: Bevacizumab', 'Drug: Fluorouracil +/- Folinic Acid']}, {'label': 'Other', 'description': 'Participants who receive bevacizumab in combination with other first-line chemotherapy regimens', 'interventionNames': ['Drug: Bevacizumab']}], 'interventions': [{'name': 'Bevacizumab', 'type': 'DRUG', 'otherNames': ['Avastin®'], 'description': 'Bevacizumab was administered as part of standard first-line treatment', 'armGroupLabels': ['Bevacizumab and Capecitabine', 'Bevacizumab and Capecitabine/Irinotecan', 'Bevacizumab and Capecitabine/Oxaliplatin', 'Bevacizumab and Fluorouracil +/- Folinic Acid', 'Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan', 'Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin', 'Other']}, {'name': 'Capecitabine/Oxaliplatin', 'type': 'DRUG', 'description': 'Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment', 'armGroupLabels': ['Bevacizumab and Capecitabine/Oxaliplatin']}, {'name': 'Fluorouracil/Folinic Acid/Oxaliplatin', 'type': 'DRUG', 'description': 'Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment', 'armGroupLabels': ['Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin']}, {'name': 'Capecitabine', 'type': 'DRUG', 'description': 'Capecitabine was administered along with bevacizumab as part of standard first-line treatment', 'armGroupLabels': ['Bevacizumab and Capecitabine']}, {'name': 'Fluorouracil/Folinic Acid/Irinotecan', 'type': 'DRUG', 'description': 'Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment', 'armGroupLabels': ['Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan']}, {'name': 'Fluorouracil +/- Folinic Acid', 'type': 'DRUG', 'description': 'Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment', 'armGroupLabels': ['Bevacizumab and Fluorouracil +/- Folinic Acid']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'BA1 3NG', 'city': 'Bath', 'country': 'United Kingdom', 'facility': 'Royal United Hospital Bath; Diabetes and Lipid Research, Wolfson Centre', 'geoPoint': {'lat': 51.3751, 'lon': -2.36172}}, {'zip': 'SL2 4HL', 'city': 'Berkshire', 'country': 'United Kingdom', 'facility': 'Wexham Park Hospital; Oncology'}, {'zip': 'B15 2TH', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Queen Elizabeth Hospital', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'B9 5SS', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Birmingham Heartlands Hospital; Dept of Oncology', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'DL14 6AD', 'city': 'Bishop Auckland', 'country': 'United Kingdom', 'facility': 'Bishop Auckland Hospital;Oncology Department', 'geoPoint': {'lat': 54.65554, 'lon': -1.67706}}, {'zip': 'FY3 8NR', 'city': 'Blackpool', 'country': 'United Kingdom', 'facility': 'University Hospital of North Staffordhire', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'zip': 'BD9 6RJ', 'city': 'Bradford', 'country': 'United Kingdom', 'facility': 'Bradford Royal Infirmary; Dept of Medical Oncology C/O Ward15', 'geoPoint': {'lat': 53.79391, 'lon': -1.75206}}, {'zip': 'BS2 8ED', 'city': 'Bristol', 'country': 'United Kingdom', 'facility': 'Bristol Haematology and Oncology Centre', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'IP33 2QZ', 'city': 'Bury St Edmunds', 'country': 'United Kingdom', 'facility': 'West Suffolk Hospital Nhs Trust; Gi Corridor', 'geoPoint': {'lat': 52.2463, 'lon': 0.71111}}, {'zip': 'CT1 3NG', 'city': 'Canterbury', 'country': 'United Kingdom', 'facility': 'Kent & Canterbury Hospital', 'geoPoint': {'lat': 51.27904, 'lon': 1.07992}}, {'zip': 'CA2 7HY', 'city': 'Carlisle', 'country': 'United Kingdom', 'facility': 'Cumberland Infirmary; Oncology Department', 'geoPoint': {'lat': 54.8951, 'lon': -2.9382}}, {'zip': 'CM1 7ET', 'city': 'Chelsmford', 'country': 'United Kingdom', 'facility': 'Broomfield Hospital; Oncology'}, {'zip': 'TS19 8PE', 'city': 'Cleveland', 'country': 'United Kingdom', 'facility': 'University Hospital North Tees', 'geoPoint': {'lat': 51.52361, 'lon': -0.32271}}, {'zip': 'HU16 5JQ', 'city': 'Cottingham', 'country': 'United Kingdom', 'facility': 'Castle Hill Hospital; Academic Oncology', 'geoPoint': {'lat': 52.50243, 'lon': -0.7554}}, {'zip': 'DL3 6HX', 'city': 'Darlington', 'country': 'United Kingdom', 'facility': 'Darlington Memorial Hospital', 'geoPoint': {'lat': 54.52429, 'lon': -1.55039}}, {'zip': 'DY1 2HQ', 'city': 'Dudley', 'country': 'United Kingdom', 'facility': 'Russells Hall Hospital; Dept of Hematology', 'geoPoint': {'lat': 52.5, 'lon': -2.08333}}, {'zip': 'DH15TW', 'city': 'Durham', 'country': 'United Kingdom', 'facility': 'University Hospital of North Durham; Oncology', 'geoPoint': {'lat': 54.77676, 'lon': -1.57566}}, {'zip': 'HG2 8AY', 'city': 'Harrogate', 'country': 'United Kingdom', 'facility': 'Harrogate Hospital', 'geoPoint': {'lat': 53.99078, 'lon': -1.5373}}, {'zip': 'HA1 3UJ', 'city': 'Harrow', 'country': 'United Kingdom', 'facility': 'Northhwick Park Hospital;Oncology Department', 'geoPoint': {'lat': 51.57835, 'lon': -0.33208}}, {'zip': 'IP4 5PD', 'city': 'Ipswich', 'country': 'United Kingdom', 'facility': 'Ipswich Hospital; Oncology Pharmacy', 'geoPoint': {'lat': 52.05917, 'lon': 1.15545}}, {'zip': 'DY11 6RJ', 'city': 'Kidderminster', 'country': 'United Kingdom', 'facility': 'Kidderminster Hospital; Oncology Dept', 'geoPoint': {'lat': 52.38819, 'lon': -2.25}}, {'zip': 'NW3 2QG', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Royal Free Hospital; Dept of Oncology', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE1 9RT', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Guys Hosp./Med. Onc./3rd Fl. T; Clinical Trial Office', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE18 4QH', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Queen Elizabeth Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SK10 3BL', 'city': 'Macclesfield', 'country': 'United Kingdom', 'facility': 'Macclesfield District General Hospital', 'geoPoint': {'lat': 53.26023, 'lon': -2.12564}}, {'zip': 'ME16 9QQ', 'city': 'Maidstone', 'country': 'United Kingdom', 'facility': 'Maidstone & Tonbridge Wells Hospital; Kent Oncology Center', 'geoPoint': {'lat': 51.26667, 'lon': 0.51667}}, {'zip': 'TS4 3BW', 'city': 'Middlesbrough', 'country': 'United Kingdom', 'facility': 'The James Cook University Hospital', 'geoPoint': {'lat': 54.57623, 'lon': -1.23483}}, {'zip': 'NE7 7DN', 'city': 'Newcastle upon Tyne', 'country': 'United Kingdom', 'facility': 'Freeman Hospital', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'NE29 8NH', 'city': 'North Shields', 'country': 'United Kingdom', 'facility': 'North Tyneside General Hospital', 'geoPoint': {'lat': 55.01646, 'lon': -1.44925}}, {'zip': 'HA6 2RN', 'city': 'Northwood', 'country': 'United Kingdom', 'facility': 'Mount Vernon Cancer Centre', 'geoPoint': {'lat': 51.61162, 'lon': -0.42454}}, {'zip': 'NG5 1PB', 'city': 'Nottingham', 'country': 'United Kingdom', 'facility': 'Nottingham University Hospitals City Campus', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'PE3 9GZ', 'city': 'Peterborough', 'country': 'United Kingdom', 'facility': 'Peterborough City Hospital, Edith Cavell Campus; Oncology Department', 'geoPoint': {'lat': 52.57364, 'lon': -0.24777}}, {'zip': 'PL6 8DH', 'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'Derriford Hospital; Gastroenterology', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'RM7 0AG', 'city': 'Romford', 'country': 'United Kingdom', 'facility': "Queen's Hospital", 'geoPoint': {'lat': 51.57515, 'lon': 0.18582}}, {'zip': 'DN16 7BH', 'city': 'Scunthorpe', 'country': 'United Kingdom', 'facility': 'Scunthorpe General Hospital; Dept of Oncology', 'geoPoint': {'lat': 53.57905, 'lon': -0.65437}}, {'zip': 'ST16 3SA', 'city': 'Stafford', 'country': 'United Kingdom', 'facility': 'Stafford Hospital; Oncology Department', 'geoPoint': {'lat': 52.80521, 'lon': -2.11636}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'country': 'United Kingdom', 'facility': 'The Royal Marsden Hospital', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'zip': 'SN3 6BB', 'city': 'Swindon', 'country': 'United Kingdom', 'facility': 'Great Western Hospital, Swindon Cancer Research Unit; Osprey Unit Level 3', 'geoPoint': {'lat': 51.55797, 'lon': -1.78116}}, {'zip': 'TQ2 7AA', 'city': 'Torquay', 'country': 'United Kingdom', 'facility': 'Torbay Hospital; Oncology', 'geoPoint': {'lat': 50.46198, 'lon': -3.52522}}, {'zip': 'TR1 3LJ', 'city': 'Truro', 'country': 'United Kingdom', 'facility': 'Royal Cornwall Hospital; Dept of Clinical Oncology', 'geoPoint': {'lat': 50.26526, 'lon': -5.05436}}, {'zip': 'WS2 9PS', 'city': 'Walsall', 'country': 'United Kingdom', 'facility': 'Walsall Manor Hospital', 'geoPoint': {'lat': 52.58528, 'lon': -1.98396}}, {'zip': 'SO22 5DG', 'city': 'Winchester', 'country': 'United Kingdom', 'facility': 'Royal Hampshire County Hospital; Winchester & Andover Breast Unit', 'geoPoint': {'lat': 51.06513, 'lon': -1.3187}}, {'zip': 'WV10 0QP', 'city': 'Wolverhampton', 'country': 'United Kingdom', 'facility': 'The Royal Wolverhampton Hospitals NHS Trust', 'geoPoint': {'lat': 52.58547, 'lon': -2.12296}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}